Tag Archives: NASDAQ:ALLO

Allogene Therapeutics Inc (ALLO) Gets a Buy Rating from William Blair

In a report released today, Raju Prasad from William Blair maintained a Buy rating on Allogene Therapeutics Inc (ALLO – Research Report). The company’s shares opened today at $26.09. According to TipRanks.com, Prasad is a 5-star analyst with an average

Allogene Therapeutics Inc (ALLO) Initiated with a Buy at William Blair

Allogene Therapeutics Inc (ALLO – Research Report) received a Buy rating from William Blair analyst Raju Prasad today. The company’s shares opened today at $26.80. Prasad commented: “Allogene Therapeutics, Inc. Just as We are initiating coverage on Outperform rating and

Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics Inc (NASDAQ: ALLO), Synlogic Inc (NASDAQ: SYBX) and Zynerba Pharmaceuticals (NASDAQ: ZYNE)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Allogene Therapeutics Inc (ALLO – Research Report), Synlogic Inc (SYBX – Research Report) and Zynerba Pharmaceuticals (ZYNE – Research Report) with bullish

J.P. Morgan Remains a Hold on Allogene Therapeutics Inc (ALLO)

J.P. Morgan analyst Cory Kasimov maintained a Hold rating on Allogene Therapeutics Inc (ALLO – Research Report) on March 8 and set a price target of $29. The company’s shares closed on Friday at $28.38. Kasimov noted: “Allogenes’s first earnings

Cowen & Co. Reaffirms Their Buy Rating on Allogene Therapeutics Inc (ALLO)

In a report released today, Phil Nadeau from Cowen & Co. maintained a Buy rating on Allogene Therapeutics Inc (ALLO – Research Report). The company’s shares opened today at $28.38. According to TipRanks.com, Nadeau is a 5-star analyst with an

Allogene Therapeutics Inc (ALLO) Received its Third Buy in a Row

After Goldman Sachs and Jefferies gave Allogene Therapeutics Inc (NASDAQ: ALLO) a Buy rating last month, the company received another Buy, this time from Cowen & Co. Analyst Phil Nadeau maintained a Buy rating on Allogene Therapeutics Inc today. The